Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (January 2022)
19 slides from Endra Life Sciences's investor presentation, Jan 7, 2022
Slide 1: Practical Assessment of Liver Fat for NAFLD-NASH
Practical Assessment of Liver Fat for NAFLD-NASH ENDRA LIFE SCIENCES WWW.ENDRAINC.COM Nasdaq NDRA N - JANUARY 2022 Russell Microcap®
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements made in this presentation are forwardooking statements. All statements other than statements of historical facts contained in presentation, including statements regarding the timing of our clinical trials, our strategy, future operations, future financia
Slide 3: About ENDRA Life Sciences
About ENDRA Life Sciences GOAL PLATFORM TECHNOLOGY Commercialize Thermo Acoustic TAEUS opportunities in a Enhanced UltraSound (TAEUS®), variety of clinical applications a technology that enhances existing ultrasound systems to visualize tissue similar to an MRI, Multiple potential revenue streams: h
Slide 4: TAEUS Platform Evolution & Business Model
TAEUS® Platform Evolution’ & Business Model START WITH LIVER ACCESSORY & SOFTWARE, THEN SCALE WITH MORE CLINICAL APPS & REVENUE STREAMS HARDWARE SOFTWARE SERVICES: DISPOSABLES LICENSING Ultrasound Apps added to “Eg, Maintenance Eg. Applicator Build TAEUS into ‘accessory accessory ‘contracts pads new
Slide 5: ENDRA's 1% Target: Large Unmet Need in NAFLD-NASH Diagnostics
ENDRA's 1% Target: Large Unmet Need in NAFLD-NASH Diagnostics RAMPANT DISEASE, APPROACHING THERAPIES ... BUT NO PRACTICAL DIAGNOSTIC TOOLS Liver Disease: NAFLD-NASH Diagnostic Gap 1s Therapies Near 1.8 billion people affected." Linked to obesity, diabetes, genetics Can progress asymptomatically to l
Slide 6: Assessing Liver Fat of 1.8 Billion NAFLD-NASH Patients
Assessing Liver Fat of 1.8 Billion NAFLD-NASH Patients NO CURRENT TOOL HAS BALANCED DIAGNOSTIC VALUE + ACCESSIBILITY OPTIMAL BALANCE DIAGNOSTIC VALUE + ACCESSIBILITY Quantitative! Ultrasound, Traditional : Ultras HIGH DIAGNOSTIC VALUE LOW ACCESSIBILITY HIGH @EMORA (AFFORDABILITY, SAFETY, EASE OF USE
Slide 7: ENDRA's TAEUS: Enhancing Traditional Ultrasound
ENDRA’s TAEUS®: Enhancing Traditional Ultrasound RADIO FREQUENCY PULSES CREATE SONIC WAVES THAT QUANTITATE LIVER FAT FRACTION Vv TAEUS directly measures a material property of liver tissue that is only yy) affected by the amount of fat (triglyceride), and has not been found to be confounded by fibro
Slide 8: TAEUS Liver Application: Targeting High-Value Segments
TAEUS® Liver Application: Targeting High-Value Segments CLINICIANS & DRUG DEVELOPERS BOTH STRUGGLE WITH MRI & BIOPSY LIMITATIONS CLINICIANS PHARMACEUTICAL COMPANIES & CRO's IMAGING, LIVER, METABOLISM TRIAL RECRUITMENT TRIAL EXECUTION COMMERCIALIZATION Radiology Reduce Measure liver fat | | Support f
Slide 9: ENDRA Partners
ENDRA Partners SUPPORTING TECHNICAL, CLINICAL & COMMERCIAL DEVELOPMENT OF TAEUS rtner's Role Value to ENDRA Build Clini Evidence Refine | Commer: Technology | Support @vPMc 7 independent TAEUS clinical e e e saad vven| @valuation sites (4 Europe, 3 U.S.) Ultrasound leader, supporting aes ENDRA intro
Slide 10: Commercializing TAEUS Liver: Core Strategies
Commercializing TAEUS Liver: 3 Core Strategies ENDRA DENERA Gon — LIFE SCIENCES HOLICO ennnt i0ue9 Europe & US. Eg, Vietnam TARGET CLINICIANS @LOCAL LEVEL Primary Mkts: ENDRA team + GE intros Secondary Markets: Distributors DRIVE AWARENESS, INTEREST & TRIAL Seas &. ARSNA publications, lu eee ting +
Slide 11: Milestones: ENDRA Liver Application
Milestones: ENDRA Liver Application Build clinical evidence, secure U.S. regulatory clearance, ramp commercialization 2021 Accomplishments 2022 Anticipated Milestones v Signed 2 partnerships with pharmaceutical * Advance/finalize U.S. TAEUS regulatory path companies: Hepion & VGI Health with FDA Y I
Slide 12: ENDRA Financial Information: As Of September 30, 2021
ENDRA Financial Information: As Of September 30, 2021 Cash Balance (Runway into 2H '22) $11.8M Common Shares Outstanding 42.2M Fully Diluted Shares Outstanding 49.9M Management / Director Ownership’ 12.0% "Based on fully diuted shares, assumes ful vesting and exercise ofall options, Refer to ENDRA's
Slide 13: Leadership & Advisors
Leadership & Advisors MANAGEMENT & $s Francois Michelon Michael Thornton Renaud Maloberti Amy Sitzler Irina Pestrikova Chairman & CEO cro cco VP Engineering Senior Director, Finance 20° years in medtech 15* years med-tech 20¢ years in medtech.12 20 yearsin engineering 10 years financial reporting, G
Slide 14: Contact Us Appendix
CONTACT US APPENDIX Yvonne Briggs LHA Investor Relations (310) 691-7100 etre - YBriggs@lhai.com www.endrainc.com See more. Do more. Live better.® NASDAQ: NDRA 14
Slide 15: Addressable Markets for TAEUS Technology: Approaches
Addressable Markets for TAEUS Technology: 3 Approaches + $19 billion market? = Enhance installed base of 380,000 cart- based ultrasound systems (best target for TAEUS accessory) x 50K TAEUS accessory (liver & future applications) 380,000" + Upside: + ENDRA services + disposables + licensing Cart-bas
Slide 16: Future TAEUS Application: Guidance of Energy-Based Therapies
Future TAEUS Application: Guidance of Energy-Based Therapies SHOW HEAT OR COLD SIGNATURE OF THERMO-ABLATIVE PROCEDURES FOR CANCER, CARDIOLOGY, PAIN THERMO-ABLATIVE PROCEDURES * 5* million procedures annually’ growing at 15%! CAGR, driven by aging-related diseases: cancer, pain, cardiology * Current
Slide 17: TAEUS Liver: Expected Clinical & Economic Value to Stakeholders
TAEUS Liver: Expected Clinical & Economic Value to Stakeholders BUILD TAEUS ON TOP OF EXISTING LIVER ULTRASOUND PROCEDURES; POTENTIAL 9 MONTH TAEUS PAYBACK HEALTHCARE PROVIDERS PATIENTS Patient: presents with one ar more of the following: ‘+ Abnormal liver function (blood tests}: ALT, AST ‘Abdominal
Slide 18: Liver Fat Measurement Tools: Relative Performance & Accessibility
Liver Fat Measurement Tools: Relative Performance & Accessibility Diagnostic Accessibility Liver Fat (Steatosis) Test AUROG" Sensitivity? Specificity? Value (Affordability, Safety, Other Considerations (ivar fat) Ease-of Use) “+ Measurement variability due to pathology interpretation Liver Biopsy Hi
Slide 19: Sources & Assumptions
Sources & Assumptions PAGE 3 1 $50K ENDRA device estimated price compared to $2.5M MAI price 2 IP Assat fled patents, issued patents and pending patent applications 3 Journal of Hopatslogy, 2018 Vol 70, Non aleohale fat Ker disease — A “Zobsr M. Younossi. Page 53 “ylobal prevalence of NAFLD in the g
ENDRA Life Sciences — Investor Presentation (January 2022) on 6ix